Data was presented at the recent American Society of Clinical Oncology's 2011 Genitourinary Cancers Symposium showing multiple protein biomarkers predictive of clinical benefit and prognostic of disease outcome in patients with advanced or metastatic renal cell cancer. This Phase III trial validated plasma cytokine and angiogenic biomarkers using Aushon's multiplex immunoassay platform...
Avila Therapeutics™, Inc., a biotechnology company developing novel targeted covalent drugs, today announced the presentation of data on AVL-292, a clinical-stage inhibitor of Bruton's tyrosine kinase (Btk), at the 16th Congress of the European Hematology Association (EHA)...
Cancer Research Technology, the commercial arm of Cancer Research UK, and Paris-based venture capital firm, Kurma Life Sciences Partners (Kurma), have launched a spin-out company, BliNK Therapeutics Ltd, to generate monoclonal antibodies using a novel platform...
A dramatically better computer tool for finding the genetic missteps that fuel cancer has been developed by St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project investigators. Researchers are using the new algorithm to help identify the chromosomal rearrangements and DNA insertions or deletions unique to cancer...
Symphogen announced preliminary data from a phase 2 clinical trial with rozrolimupab (SYM001) in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP). The study showed rozrolimupab is well tolerated with no unexpected toxicities and shows preliminary signs of clinical and biological activity by decreasing haemoglobin values...
Certain Head And Neck Cancer Patients Benefit From Second Round Of Treatment
6/13/2011
A new study has determined predictors that can better identify patients who will benefit from a potentially toxic second course of treatment, which offers a small but real chance of cure in select patients with head and neck cancer...
Link Between Long Term Mobile Phone Use And Brain Tumours
6/12/2011
Two papers have been published online in Occupational and Environmental Medicine. They show for the first time that there is a dose response effect for the risk of brain tumours among the heaviest users of mobile phones. Before this study, there was only an indication of an increased risk, but with no correlation with length of exposure, which could have been due to bias...
Staging Atlas In Thoracic Oncology For IPad, IPhone, Android And BlackBerry Launched By IASLC
6/12/2011
The International Association for the Study of Lung Cancer (IASLC), the only global organization dedicated to the study of lung cancer, today announced the release of its Staging Atlas in Thoracic Oncology as a downloadable application for iPad, iPhone, Android or BlackBerry...
Aiming To Speed Cancer Clinical Trials, NCI Partners With Jackson Laboratory, UC Davis
6/12/2011
About nine out of 10 new cancer drugs successfully clear preclinical development hurdles, but then they fail in human clinical testing. A new partnership facilitated by SAIC-Frederick Inc. aims to help change that outcome...
Carcinogens - Eight Substances Added To The List
6/12/2011
Eight substances have been added to the list of carcinogens by the HSS (US Department of Health and Human Services) today. The Report of Carcinogens has added formaldehyde, aristolochic acids, o-nitrotoluene, captafol, cobalt-tungsten carbide (in powder or hard metal form), riddelliine, certain inhalable glass wool fibers, and styrene to the list of carcinogens...